NEW YORK: The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treat Covid-19, the company said Friday.It now “anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion,“ Pfizer announced in a statement.Earnings per share - the benchmark for the markets - should come in at between 1.45 and 1.65 dollars, compared with 3.25 to 3.45 dollars previously anticipated.The cut to Pfizer’s guidance was “solely due to its COVID products,“ the company said.“Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be app
Hence then, the article about pfizer cuts earnings outlook on lower covid 19 drug sales was published today ( ) and is available onDaily Sun ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Pfizer cuts earnings outlook on lower Covid-19 drug sales )